
Cipla (CIPLA) Share Price Rises 2.82% to Rs 1,422 Today
Updated: 18 Nov 2026 • 11:26 am
Posted by:

Cipla Share Price is Rs 1,422, up 2.82% today, with a market capitalisation of Rs 1,12,619.60 Cr. The move places Cipla Share Price in the spotlight as investors track the day’s price rise, the latest company context and the healthcare backdrop.The stock opened at Rs 1,391.50, touched a high of Rs 1,425 and a low of Rs 1,382, so the day’s range has remained relatively contained around the current level. For readers following Cipla Share Price Today, the key question is whether today’s gain adds new fundamental context or is mainly a one-day price action event. The answer lies in valuation, sector positioning and the compliance update reported on the same day.
Cipla Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,422 |
| Previous Close | Rs 1,383 |
| Today's Move | Rs 39 (+2.82%) |
| Open | Rs 1,391.5 |
| High | Rs 1,425 |
| Low | Rs 1,382 |
| Market Capitalisation | Rs 1,12,619.6 crore |
| Market Cap Category | Large Cap |
Cipla Ltd. (CIPLA) rose to Rs 1,422 from the previous close of Rs 1,383, a move of Rs 39 or 2.82%. The stock opened at Rs 1,391.5, reached a high of Rs 1,425, recorded a low of Rs 1,382.
Cipla Share Price is trading at Rs 1,422, which is Rs 39 above the previous close of Rs 1,383. The share price rise of 2.82% came after an opening level of Rs 1,391.50, and the stock moved between Rs 1,382 and Rs 1,425 during the day. This makes Cipla Share Price Today a clean intraday gain rather than a broad multi-day move. The current price is also close to the day high, which keeps the focus on the immediate price action and the strength of the opening-hour move. For anyone tracking Cipla Share Price Live, the key facts are simple: the stock is higher, the range is defined, and the market capitalisation remains above Rs 1,12,000 Cr. The next layer of analysis is the fundamental backdrop behind Cipla Share Price.
Why Cipla Ltd. (CIPLA) May Be Moving Today
Cipla Ltd. (CIPLA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,12,619.6 crore |
| P/E Ratio | 38.57x |
| P/B Ratio | 3.16x |
| ROE | 11.83% |
| ROCE | 16% |
| EPS | Rs 35.86 |
| Book Value Per Share | Rs 438.12 |
| Dividend Yield | 0.94% |
Cipla Ltd. (CIPLA) fundamental metrics show P/E 38.57x, P/B 3.16x, ROE 11.83%, ROCE 16%. These ratios show where the company stands today and are not a call to buy or sell.
Cipla Ltd. has a market capitalisation of Rs 1,12,619.6 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 38.57x, P/B at 3.16x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.83% and ROCE of 16%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 35.86, book value per share of Rs 438.12, dividend yield of 0.94%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.01x, median ROE of 11.33%, median ROCE of 13.1%. Together they describe the fundamental backdrop without implying a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 38.57x |
| Benchmark Median P/E | 31.01x |
| Benchmark Average P/E | 58.7x |
| Benchmark P/E Range | 2.75x to 1,425.63x |
| Company P/B Ratio | 3.16x |
| Benchmark Median P/B | 2.88x |
| Company ROE | 11.83% |
| Benchmark Median ROE | 11.33% |
| Company ROCE | 16% |
| Benchmark Median ROCE | 13.1% |
| Company Market Capitalisation | Rs 1,12,619.6 crore |
| Benchmark Median Market Cap | Rs 791.38 crore |
Cipla Ltd. (CIPLA) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Cipla Ltd. (CIPLA) has a P/E ratio of 38.57x, which is above the benchmark median of 31.01x, a difference of +24.38%. A P/E difference of this kind is a reference point rather than a recommendation.
Cipla Ltd. (CIPLA) has a ROE of 11.83%, which is above the benchmark median of 11.33%, a difference of +4.41%. Cipla Ltd. (CIPLA) has a ROCE of 16%, which is above the benchmark median of 13.1%, a difference of +22.14%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,47,943.84 | 40.92 | 5.03 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,94,962.14 | 87.74 | 16.4 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,78,390.62 | 83.65 | 9.67 | 26.76 | 19.27 |
| Laurus Labs Ltd. | LAURUSLABS | 1,19,789.92 | 94.36 | 20.86 | 18.31 | 18.2 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,18,603.21 | 28.7 | 4.31 | 19.69 | 21.39 |
Cipla Ltd. (CIPLA) has a P/E ratio of 38.57x compared with the displayed peer median of 83.65x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.83% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 16% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Cipla Ltd. (CIPLA) has a market capitalisation of Rs 1,12,619.6 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Cipla
- Cipla Share Price is higher today at Rs 1,422, with a 2.82% gain from the previous close.
- The price move came alongside a verified USFDA NAI status update for Invagen’s US factory.
- Cipla Share Price carries a P/E of 38.57 and a P/B of 3.16, both above the industry medians.
- ROE of 11.83% and ROCE of 16% give Cipla Share Price a measurable return profile within Healthcare.
- Peer comparison places Cipla Share Price between lower- and higher-valued pharmaceutical names on P/E and return ratios.
About Cipla Ltd.
Cipla Ltd. operates in Healthcare and the Pharmaceuticals & Drugs industry. Cipla Share Price reflects a business that is followed for its pharma presence in India and its wider manufacturing and market access footprint. The company’s described business context is pharmaceutical in nature, and the verified news item on the day relates to its subsidiary Invagen’s US manufacturing facility receiving NAI status from the USFDA. That is relevant to the company’s manufacturing compliance context, but the broader business view remains centred on drugs and healthcare. For Cipla Share Price Today, the key company-level facts are its sector, industry, market capitalisation and listed valuation profile. Univest tracks Cipla Share Price as a healthcare name with meaningful scale, and the company’s ratios place it within a comparably dense pharmaceutical peer universe.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
What is Cipla Share Price today?
Ans. Cipla Share Price is Rs 1,422, which is Rs 39 above the previous close of Rs 1,383. The stock is up 2.82% today, and the move keeps Cipla Share Price in focus for intraday tracking.
Why is Cipla Share Price rising today?
Ans. According to latest Univest data, the price event is confirmed, and the day also carried a verified USFDA NAI status report for Invagen’s US factory.
What is Cipla market capitalisation?
Ans. Cipla’s market capitalisation is Rs 1,12,619.60 Cr. That places Cipla Share Price well above the industry benchmark median market capitalisation and gives the company a sizable position in Healthcare.
How does Cipla Share Price compare on P/E?
Ans. Cipla Share Price has a P/E ratio of 38.57, above the same-industry median of 31.01 and below the industry average of 58.7. That places it above the benchmark median but not at the highest end.
How does Cipla compare on P/B ratio?
Ans. Cipla’s P/B ratio is 3.16. It is slightly above the industry median of 2.88 and close to the benchmark average of 3.29, which keeps Cipla Share Price near the centre of the valuation band.
What do Cipla ROE and ROCE show?
Ans. Cipla reports ROE of 11.83% and ROCE of 16%. ROE is just above the sector median, while ROCE is above the benchmark median of 13.1%, giving Cipla Share Price a steady return profile.
What is Cipla EPS and book value?
Ans. Cipla’s EPS is Rs 35.86 and book value is Rs 438.12 per share. EPS shows earnings attributable to each share, while book value shows the accounting net worth behind each share for Cipla Share Price analysis.
What is Cipla dividend yield?
Ans. Cipla’s dividend yield is 0.94%. It is a historical or current payout measure rather than a guarantee of future income, and it adds another factual layer to Cipla Share Price analysis.
Track Cipla Share Price on Univest
Use Cipla Ltd. (CIPLA) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Track Cipla Share Price on Univest for live price updates, valuation ratios, market capitalisation, 52-week levels and company insights. Univest brings Cipla Share Price Today, Cipla Share Price Live and Cipla Stock News into one place so readers can follow price action, fundamentals and peer comparison together. It is a practical way to monitor Cipla Share Price Update alongside sector context and listed peer metrics without relying on fragmented sources. For investors who want a cleaner view of Cipla Share Price, Univest keeps the core data points in one place.
Recent Articles

JA Finance Ltd. Hits Lower Circuit for the 2nd Straight Session on BSE, 18 November 2026
18 November 2026

Gold Price Today: Spot Gold Slips Below $3,800 an Ounce for the First Time Since September 2025 as MCX Gold Falls 2% to Rs 1,31,420 With the Dollar Firm and FOMC Minutes Due
18 November 2026

TCS Share Price Down 26% in 2026: What the Technical Charts Show at Rs 2,389, an RSI of 33, Key Support and Resistance Levels to Watch and What Q2 Results and Valuation Say About the Buying-Opportunity Debate
18 November 2026

Vedant Poly Fabs Ltd. Hits Lower Circuit for the 2nd Straight Session on NSE, 18 November 2026
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
JA Finance Ltd. Hits Lower Circuit for the 2nd Straight Session on BSE, 18 November 2026
Gold Price Today: Spot Gold Slips Below $3,800 an Ounce for the First Time Since September 2025 as MCX Gold Falls 2% to Rs 1,31,420 With the Dollar Firm and FOMC Minutes Due
TCS Share Price Down 26% in 2026: What the Technical Charts Show at Rs 2,389, an RSI of 33, Key Support and Resistance Levels to Watch and What Q2 Results and Valuation Say About the Buying-Opportunity Debate
Vedant Poly Fabs Ltd. Hits Lower Circuit for the 2nd Straight Session on NSE, 18 November 2026
Salasar Techno Engineering Share Price Jumps as Much as 11.6% to Rs 6.45 as a Three-Day Rally Nears 42%: Why Reported Profit Is Distorted by a Tax Credit, What the Operating Numbers Show and How Overbought the Stock Looks
Popular this week
Midwest Gold Ltd. Hits Lower Circuit on BSE, 18 November 2026

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





